PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
856.01
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.91. Michael Burry would check for market euphoria. Scrutinize growth expectations.
619.53
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.76. Jim Chanos would check for potential multiple compression risks.
25.30
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.07. Jim Chanos would check for potential asset write-down risks.
-779.58
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
5465.79
P/OCF of 5465.79 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
25.30
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.07. Jim Chanos would check for valuation bubble risks.
0.03%
Earnings yield below 50% of Drug Manufacturers - Specialty & Generic median of 0.14%. Jim Chanos would check for earnings sustainability risks.
-0.13%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.